FLOVENT DISKUS 100 Drug Patent Profile

When do Flovent Diskus 100 patents expire, and what generic alternatives are available?

Flovent Diskus 100 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in FLOVENT DISKUS 100 is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Flovent Diskus 100

A generic version of FLOVENT DISKUS 100 was approved as fluticasone propionate by ENCUBE on May 14^th, 2004.

Summary for FLOVENT DISKUS 100

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	19
Patent Applications:	2,700
DailyMed Link:	FLOVENT DISKUS 100 at DailyMed

Recent Clinical Trials for FLOVENT DISKUS 100

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Respirent Pharmaceuticals Co Ltd.	Phase 1
Becro Ltd.	Phase 1
Respirent Pharmaceuticals Co Ltd.	Phase 3

See all FLOVENT DISKUS 100 clinical trials

Pharmacology for FLOVENT DISKUS 100

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for FLOVENT DISKUS 100

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	FLOVENT DISKUS 100	fluticasone propionate	POWDER;INHALATION	020833-002	Sep 29, 2000		RX	Yes	Yes

International Patents for FLOVENT DISKUS 100

See the table below for patents covering FLOVENT DISKUS 100 around the world.

Country	Patent Number	Title	Estimated Expiration
Ireland	810282
African Intellectual Property Organization (OAPI)	9393
Italy	RM910145

Supplementary Protection Certificates for FLOVENT DISKUS 100

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1519731	132013902182575	Italy		PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
2506844	18C1022	France		PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117

Flovent Diskus 100: Market Dynamics and Financial Trajectory

Last updated: April 26, 2026

What is Flovent Diskus 100 in commercial terms?

Flovent Diskus 100 mcg (fluticasone propionate) is an inhaled corticosteroid (ICS) used for maintenance treatment of asthma. Commercially, it sits in the U.S. respiratory controller market where demand is driven by guideline-based chronic management, insurance coverage, and formulary positioning.

Key practical framing for market dynamics:

• Therapeutic class: inhaled corticosteroid (anti-inflammatory controller)
• Route/form: dry powder inhaler (DPI), Diskus platform
• Dose strength: 100 mcg per actuation (adult/pediatric dosing varies by regimen)
• Market behavior: chronic use, refill-driven sales, and high payer sensitivity to coverage and step-therapy

How do patent, exclusivity, and generic erosion shape its market?

Flovent’s competitive structure is defined by loss of brand exclusivity and long-run generic substitution across strengths and delivery devices. In practical commercial terms:

• Brand sales typically decay after exclusivity ends as multiple ANDA competitors enter.
• Remaining brand volumes then depend on formulary placement, patient-assistance channels, and device-related switching friction (brand DPI vs generic DPI).

For business planning, the core point is that Flovent Diskus 100 is exposed to the same market mechanics as other legacy ICS brands: pricing power compresses quickly post-generic entry, while demand persists but shifts to lower-cost equivalents.

What drives demand year to year?

Flovent Diskus 100 demand tracks the intersection of asthma prevalence, guideline adherence, and payer utilization management:

1. Asthma controller persistence

   • ICS therapy is long-duration, so steady refill behavior supports baseline demand.
   • Controller adherence can fall during economic stress or after policy changes, but the category generally retains a “chronic” demand profile.

2. Formulary design and step therapy

   • Many payers prefer preferred ICS options in tiered formularies.
   • If equivalent generics are on preferred tiers, brand retention becomes harder.

3. Generic breadth and switching

   • When multiple generic products exist, pharmacy-level substitution increases.
   • Even when brand substitution is restricted, prescribers often write “equivalent” alternatives, compressing brand share.

4. Device competition

   • DPI availability across competitors changes the “best available” device pick over time.
   • Patient switching can occur when contracts change.

Where does Flovent Diskus 100 sit versus competing inhaled corticosteroids?

Competitive positioning in the ICS space is typically evaluated on:

• Therapeutic equivalence (same active ingredient at clinically comparable dosing)
• Net price after rebates
• Payer preference and PBM formulary design
• Device acceptability and inhalation technique learning curve

In practice, Flovent Diskus 100 competes against:

• Other ICS molecules (e.g., budesonide, beclomethasone, mometasone products depending on label availability)
• Other fluticasone presentations and inhaler devices
• Generic fluticasone DPIs and equivalents at lower cost

When generics are broadly available, the economics tilt toward the lowest net-cost preferred option, leaving brand incumbents with narrower windows for volume retention.

What does the financial trajectory typically look like for a legacy ICS brand?

For a legacy ICS like Flovent Diskus 100, financial trajectory typically follows a sequence:

• Pre-erosion period: brand pricing and exclusivity support higher revenue and operating margins.
• Post-entry/generic pressure: revenue declines as share migrates to generics; price per unit drops; margin compresses.
• Mature branded phase (if any): residual brand sales persist but are increasingly driven by non-clinical factors (coverage carve-outs, switching barriers, channel contracts, and patient preferences).

A common outcome in mature inhaled controller markets is that the brand:

• retains some volume, but
• shifts from a growth profile to a decline-and-defend profile.

How do reimbursement and channel dynamics affect revenue?

Flovent Diskus 100’s revenue sensitivity is tied to the U.S. reimbursement mechanics:

• PBM contracting and formulary tiers determine whether Flovent remains a preferred option.
• Rebates and discounts influence the net price the payer effectively pays.
• Patient cost-sharing impacts adherence and switching behavior, especially at deductible resets.
• Channel mix (commercial vs Medicaid vs Medicare) affects baseline purchasing behavior.

In mature brands, net revenue is often more volatile than units because:

• rebate pressure rises to defend formulary access, and
• net-to-gross shifts with contract renegotiations.

What are the key market dynamics watchpoints?

For Flovent Diskus 100, the most decision-relevant market dynamics are these:

• Formulary moves by top PBMs (preferred vs non-preferred placement)
• Competitor generics expansion (more SKUs and lower-cost entries)
• Net price pressure from contracting dynamics
• Device-level preference if competitors maintain better inhaler usability positioning
• Policy shifts impacting utilization management (step therapy controls, coverage rules)
• Asthma prevalence and diagnosis trends (baseline demand)
• Seasonality (respiratory infection seasons drive ICS persistence and refill cycles)

What is the financial trajectory based on the available public footprint?

No specific revenue, unit sales, or financial statements for Flovent Diskus 100 are provided in the information available here. A complete financial trajectory requires product-specific sales reporting and/or company segment disclosures mapped to this SKU and strength.

Given that constraint, the actionable business conclusion is limited to the structural trajectory drivers:

• Expect sustained share pressure from generics in the fluticasone DPI landscape.
• Expect net price compression tied to payer contracting.
• Expect a mature market pattern where growth is unlikely absent device switching advantages or formulary re-preference.

Market outlook: what changes could improve or worsen the trajectory?

What would improve performance

• Restored preferred placement under major payer contracts
• Reduced generic price pressure through fewer contracted options (rare in mature generics)
• Patient-device preference that reduces switching to lower-cost alternatives
• Targeted adherence programs tied to insurance retention and refill optimization

What would worsen performance

• Loss of preferred formulary tier and increased patient out-of-pocket costs
• Further strengthening of step therapy enforcement
• Expanded generic SKU competition and deeper discounting
• Device switching acceleration if inhaler technique supports competitor DPI adoption

Key Takeaways

• Flovent Diskus 100 is a legacy branded ICS in a mature therapeutic area where generic substitution drives long-run decline.
• Revenue trajectory is dominated by formulary placement, PBM contracting, net price erosion, and rebate pressure rather than by clinical innovation.
• The market behaves like a chronic refill product, so demand persists, but brand share typically migrates to generics once exclusivity ends.
• Near-term outcomes hinge on contracting and formulary tier status with major payers, plus device-level switching behavior.

FAQs

1. Is Flovent Diskus 100 primarily a generic-substitution market or a differentiation market?
   It is primarily a generic-substitution market because the active ingredient is widely available and payer cost containment favors lower-cost equivalent options.

2. What most affects Flovent Diskus 100 sales: unit demand or net price?
   Both matter, but in mature legacy brands, net price (after rebates and contracting) typically drives the largest swings in revenue outcomes even when unit demand remains relatively steady.

3. Does seasonality impact Flovent Diskus 100 performance?
   Yes. ICS controller refills often show seasonality tied to respiratory illness patterns, which can influence adherence and reorder rates.

4. How do PBM formulary changes translate into revenue changes for legacy inhalers?
   Formulary movement changes patient access and pharmacy substitution behavior, typically causing faster share loss when a brand shifts to non-preferred status.

5. What is the biggest competitive threat to Flovent Diskus 100?
   The biggest threat is expanded generic fluticasone DPI competition combined with aggressive net-cost contracting that pushes prescribers and pharmacies toward preferred lower-cost equivalents.

References

No sources were provided in the input for Flovent Diskus 100-specific market size, sales, financials, exclusivity timelines, or patent status.